Browsing Clinical Studies by author "Snowdon, Claire"
Now showing items 1-12 of 12
-
Cediranib in patients with alveolar soft-part sarcoma (CASPS): a double-blind, placebo-controlled, randomised, phase 2 trial.
Judson, I; Morden, JP; Kilburn, L; Leahy, M; Benson, C; et al. (ELSEVIER SCIENCE INC, 2019-07-01)BACKGROUND: Alveolar soft-part sarcoma (ASPS) is a rare soft-tissue sarcoma that is unresponsive to chemotherapy. Cediranib, a tyrosine-kinase inhibitor, has shown substantial activity in ASPS in non-randomised studies. ... -
Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial.
Turner, NC; Kingston, B; Kilburn, LS; Kernaghan, S; Wardley, AM; et al. (ELSEVIER SCIENCE INC, 2020-10-01)BACKGROUND: Circulating tumour DNA (ctDNA) testing might provide a current assessment of the genomic profile of advanced cancer, without the need to repeat tumour biopsy. We aimed to assess the accuracy of ctDNA testing ... -
Conducting non-commercial international clinical trials: the ICR-CTSU experience.
Fox, L; Toms, C; Kernaghan, S; Snowdon, C; Bliss, JM (BMC, 2017-09-26)BACKGROUND: Academic clinical trials play a fundamental role in the development of new treatments, the repurposing of existing treatments and in addressing areas of unmet clinical need. With cancer treatments increasingly ... -
Costs and staffing resource requirements for adaptive clinical trials: quantitative and qualitative results from the Costing Adaptive Trials project.
Wilson, N; Biggs, K; Bowden, S; Brown, J; Dimairo, M; et al. (BMC, 2021-10-26)BACKGROUND: Adaptive designs offer great promise in improving the efficiency and patient-benefit of clinical trials. An important barrier to further increased use is a lack of understanding about which additional resources ... -
Life After COVID-19 for Cancer Clinical Trials.
Hall, E; Lewis, R; Snowdon, C (ELSEVIER SCIENCE INC, 2020-10-01) -
Long-Term Follow-Up of the Intergroup Exemestane Study.
Morden, JP; Alvarez, I; Bertelli, G; Coates, AS; Coleman, R; et al. (LIPPINCOTT WILLIAMS & WILKINS, 2017-08-01)Purpose The Intergroup Exemestane Study, an investigator-led study of 4,724 postmenopausal patients with early breast cancer (clinical trial information: ISRCTN11883920), has previously demonstrated that a switch from ... -
Patient advocate involvement in the design and conduct of breast cancer clinical trials requiring the collection of multiple biopsies.
Batten, LM; Bhattacharya, IS; Moretti, L; Haviland, JS; Emson, MA; et al. (Springer Science and Business Media LLC, 2018-01-01)PLAIN ENGLISH SUMMARY: Breast cancer is a diverse and varied disease. Recent research has shown that the collection of multiple biopsies before surgery can help researchers determine how the cancer is responding to treatment ... -
Practical guidance for planning resources required to support publicly-funded adaptive clinical trials.
Wason, JMS; Dimairo, M; Biggs, K; Bowden, S; Brown, J; et al. (BMC, 2022-08-10)Adaptive designs are a class of methods for improving efficiency and patient benefit of clinical trials. Although their use has increased in recent years, research suggests they are not used in many situations where they ... -
Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial.
Johnston, S; Puhalla, S; Wheatley, D; Ring, A; Barry, P; et al. (AMER SOC CLINICAL ONCOLOGY, 2019-01-20)PURPOSE: CDK4/6 inhibitors are used to treat estrogen receptor (ER)-positive metastatic breast cancer (BC) in combination with endocrine therapy. PALLET is a phase II randomized trial that evaluated the effects of combination ... -
Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer.
Turner, NC; Swift, C; Jenkins, B; Kilburn, L; Coakley, M; et al. (ELSEVIER, 2022-11-21)BACKGROUND: Post-treatment detection of circulating tumour DNA (ctDNA) in early-stage triple-negative breast cancer (TNBC) patients predicts high risk of relapse. c-TRAK TN assessed the utility of prospective ctDNA ... -
The Application and Feasibility of Using Routine Data Sources for Long-term Cancer Clinical Trial Follow-up.
Bhattacharya, IS; Morden, JP; Griffin, C; Snowdon, C; Brannan, R; et al. (2017-12) -
The UK plasma based molecular profiling of advanced breast cancer to inform therapeutic choices (plasmamatch) trial: a multiple parallel cohort, open-label, multi-centre phase IIa clinical trial aiming to provide proof of principle efficacy for designated targeted therapies in patients with advanced breast cancer where the targetable mutation is identified through ctDNA screening (CRUK/15/010)
Bliss, J; Kernaghan, S; Fribbens, C; Stevenson, L; Morden, J; et al. (BIOMED CENTRAL LTD, 2017-05-08)